Meet the Value Stock With a 6.6% Dividend Yield That's Begging to Be Bought in April

General Mills is forecasting a 16%–20% decline in fiscal 2026 adjusted EPS (following a 7% decline in fiscal 2025) while the stock has fallen ~36.7% over the past year and ~40% over the past decade. The dividend yield has risen to 6.6% and management says the payout is affordable based on free cash flow guidance amid ongoing cost cuts and balance-sheet improvements. The company is emphasizing protein- and fiber-focused innovation (Cheerios Protein launched Dec 2024, forecasted as a $100M brand, plus expanded 'Ghost' protein offerings) to capture shifting consumer demand. Inflationary pressures, including rising oil, are compressing margins, but the article presents GIS as a high-conviction, value/dividend buy for patient income investors.

Analysis

General Mills' pivot toward higher-protein and higher-fiber SKUs is a product-mix lever that can meaningfully raise realized selling price per ounce without requiring a full restoration of historic unit volumes; every +100bps mix shift toward premium protein SKUs should be able to recover a disproportionate share of margin lost to commodity inflation because these SKUs carry higher gross margins and lower promo intensity. That same mix shift creates second-order demand for specialty protein inputs (pea, whey, collagen) and packaging for single-serve bars — suppliers of those inputs and co-packers will see order growth ahead of bulk commodity processors, tightening those bottlenecks and raising supplier bargaining power over the next 6–18 months.

Key catalysts to watch are near-term: the next two quarterly prints (weeks to months) for volume/mix trends and FY26 mid-year guidance sanity checks, and medium-term: sales velocity and repeat rates for new protein SKUs over 6–12 months. Tail risks include persistent GLP-1-induced downtrading in pantry staples that shrinks frequency of category purchases (not just size), and another oil/commodity shock that widens the gap between input inflation and shelf price realization; either could force a faster and larger FCF correction and, in the extreme, a dividend reset within 12–18 months.

The opportunity is asymmetric if you believe the market is underrating branded premium-snack resilience vs. commoditized frozen categories: a successful product mix recovery combined with modest multiple re-rating could produce 30–50% total return in 12–24 months, while a downside sequence of accelerating volume loss leaves room for 20–35% drawdowns despite dividend support. That makes structured long exposure with explicit, time-bound hedges preferable to a naked directional stake — size and option structure should be calibrated to a 12–18 month horizon tied to measurable product adoption metrics.

Key Decisions for Investors

• Core position: Buy GIS shares sized 3–5% of equity portfolio as a 12–24 month recovery play; target total return +40% (price + dividends) if FY26/FY27 EPS recovers 15–25% and multiples re-rate. Hedge: buy Jun 2026 15% OTM puts to cap downside (~15–20%) and fund by selling Jun 2026 covered calls ~15% OTM. Risk: if volumes continue to fall, expect 20–30% paper drawdown before hedge payoff.
• Relative-value pair: Long GIS / Short KO, equal-dollar, 6–12 month horizon to express a beat-on-mix thesis while neutralizing broad staples beta. Reward: expect 15–30% relative outperformance if GIS' protein/fiber mix gains translate to margin recovery; risk: underperformance if beverage defensives rerate or GIS’ mix fails to scale.
• Optionality play: Buy 12–18 month GIS call options (LEAPS or Jun 2027) ~25–35% OTM sized 0.5–1% of portfolio to capture asymmetric upside from successful product launches (low cash outlay). Risk: full premium loss if adoption disappoints; reward: 3x–5x+ if core SKUs hit $100M+ run-rates and multiple re-rating follows within 12–18 months.